Medical News / ACC House Call: Where Will SGLT-2 Inhibitors Go Now?

If the opinion of Muthiah Vaduganathan, MD, MPH, on what data best defined cardiometabolic research in 2019—DAPA-HF and CREDENCE—is true, then what will define this year and next? In a special edition House Call video conference interview with HCPLive®, Vaduganathan, a cardiologist at the Center for Advanced Heart Disease at Brigham and Women's Hospital, discussed SGLT2 trial data on the eve of the virtual kickoff for the American College of Cardiology (ACC) 2020 Scientific Sessions. Source: MDMag. By reading more or clicking on the link below, you are leaving this site and going to another site run by another organization.

read more

Few surgical advances this century have had an impact equal to that of transcatheter aortic valve ... read more
While the American College of Cardiology’s Annual Scientific Session Together with World Congress of Cardiology (ACC.20/WCC) ... read more
Results of a new study are offering clinicians guidance on optimal timing of menopausal hormone replacement ... read more
The clinical discussion as to whether electronic cigarette devices has already begun. But debate still wages ... read more